

Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).

NCT04663750

Status	RECRUITING
Phase	Phase 3
Sponsor	King's College Hospital NHS Trust
Enrollment	210 participants

Key Eligibility Criteria

Inclusion (7)

- General
 - Males or females aged at least 50 years
 - Study eye
 - SMH, comprising sub-neuroretinal haemorrhage with or without sub-RPE haemorrhage, that occurs secondary to treatment naïve, or previously treated exudative AMD, including choroidal neovascularisation (CNV), idiopathic polypoidal choroidal vasculopathy (IPCV) and retinal angiomatous proliferation (RAP).
 - SMH involving the foveal centre that measures at least 1 disc diameter in greatest linear dimension.
- ... and 2 more (see full listing online)

Exclusion (21)

- General
 - Serious allergy to fluorescein or indocyanine green (ICG).
 - Hypersensitivity to alteplase, gentamicin, arginine, phosphoric acid, polysorbate 80 or aflibercept (Eylea).
 - Stroke, transient ischaemic attack or myocardial infarction within 6 months.
 - Participation in another interventional study within 12 weeks of enrolment or planned to occur during this study.
- ... and 16 more (see full listing online)

Locations (36 total)

University of Bonn, Bonn, Germany
University Medical Center Hamburg Eppendorf, Hamburg, Germany
Ludwig Maximilians-University München, München, Germany
... and 33 more locations